Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delgocitinib Cream in Frontal Fibrosing Alopecia
NCT05332366Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of delgocitinib in frontal fibrosing alopecia (FFA) (3 arms), sponsored by LEO Pharma. Primary endpoint: Change in Expression of Chemokine (C-X-C Motif) Ligand 9, Chemokine (C-X-C Motif) Ligand 10, and Interferon-gamma at 12 weeks. Started Apr 2022; status: completed.
02
Drugs
delgocitinib
03
Conditions
frontal fibrosing alopecia (FFA)
Beyond the preview
Go deeper on NCT05332366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332366.